ASKA Pharmaceutical Holdings Co.,Ltd. Share Price

Equities

4886

JP3119660003

Pharmaceuticals

Market Closed - Japan Exchange 11:30:00 19/07/2024 am IST 5-day change 1st Jan Change
2,387 JPY +0.59% Intraday chart for ASKA Pharmaceutical Holdings Co.,Ltd. -1.40% +33.80%

Financials

Sales 2025 * 64.02B 406M 34.02B Sales 2026 * 67.79B 430M 36.03B Capitalization 67.62B 429M 35.94B
Net income 2025 * 5.24B 33.27M 2.79B Net income 2026 * 5.24B 33.22M 2.78B EV / Sales 2025 * 0.86 x
Net cash position 2025 * 12.31B 78.09M 6.54B Net cash position 2026 * 17.19B 109M 9.14B EV / Sales 2026 * 0.74 x
P/E ratio 2025 *
12.9 x
P/E ratio 2026 *
12.9 x
Employees 762
Yield 2025 *
2.09%
Yield 2026 *
2.14%
Free-Float 0%
More Fundamentals * Estimated data
Dynamic Chart
Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021. CI
ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback announced on July 12, 2021, has closed with 300,000 shares, representing 1.06% for ¥316.48 million. CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021. CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021. CI
ASKA Pharmaceutical Holdings Co.,Ltd. announces an Equity Buyback for 300,000 shares, representing 1.05% for ¥350 million. CI
ASKA Pharmaceutical Holdings Co.,Ltd. authorizes a Buyback Plan. CI
ASKA Pharmaceutical Holdings Co., Ltd. acquired 20.04% stake in Japan Glass Industry Co., Ltd. CI
Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and Development CI
ASKA Pharmaceutical Co., Ltd. acquired additional 20% stake in Ha Tay Pharmaceutical JSC. CI
ASKA Pharmaceutical Co., Ltd. completed the acquisition of 24.9% stake in Ha Tay Pharmaceutical JSC. CI
Ha Tay Pharmaceutical JSC announced that it has received VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd. CI
Ha Tay Pharmaceutical JSC announced that it expects to receive VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd. and other investors CI
ASKA Pharmaceutical Co., Ltd. signed an agreement to acquire 24.9% stake in Ha Tay Pharmaceutical JSC. CI
More news
1 day+0.59%
1 week-1.40%
Current month-3.79%
1 month-1.73%
3 months+8.16%
6 months+29.24%
Current year+33.80%
More quotes
1 week
2 358.00
Extreme 2358
2 430.00
1 month
2 358.00
Extreme 2358
2 720.00
Current year
1 787.00
Extreme 1787
2 720.00
1 year
1 471.00
Extreme 1471
2 720.00
3 years
919.00
Extreme 919
2 720.00
5 years
776.00
Extreme 776
2 720.00
10 years
776.00
Extreme 776
2 720.00
More quotes
Managers TitleAgeSince
President 72 01/21/01
Chief Administrative Officer - -
Compliance Officer - 01/21/01
Members of the board TitleAgeSince
President 72 01/21/01
Director/Board Member 65 01/21/01
Director/Board Member 75 01/21/01
More insiders
Date Price Change Volume
19/24/19 2,387 +0.59% 34,800
18/24/18 2,373 -0.08% 59,800
17/24/17 2,375 -0.96% 70,500
16/24/16 2,398 -0.95% 56,400
12/24/12 2,421 +0.88% 51,900

Delayed Quote Japan Exchange, July 19, 2024 at 11:30 am IST

More quotes
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2,387 JPY
Average target price
2,450 JPY
Spread / Average Target
+2.64%
Consensus